Abstract
Objective: To compare the efficacy and tolerance of single-dose grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in women.
Methods: Women attending nine sexually-transmitted-disease clinics in the United States who had suspected uncomplicated gonorrhea were enrolled in an open study. Participants were randomized to receive single oral doses of grepafloxacin (400 mg) or cefixime (400 mg), and efficacy was evaluated in those who returned for follow-up assessment 5 to 10 days later. The primary measure of efficacy was microbiological response to therapy as determined by pre- and posttreatment culture results for Neisseria gonorrhoeae.
Results: Of 380 patients enrolled, 124 in the grepafloxacin group and 131 in the cefixime group were evaluated for microbiological response. Cervical gonococcal infections were eradicated in 99% of patients in both treatment groups, with only one persistent infection in each group. All pharyngeal (n = 15) and rectal (n = 32) gonococcal infections treated with grepafloxacin were cured, whereas 5 of 16 (31%) pharyngeal and 1 of 38 (3%) rectal infections failed to respond to cefixime. Although a third (123 of 386) of N. gonorrhoeae pretreatment isolates were resistant to penicillin or tetracycline, this had no impact on cure rates. Both drugs were well tolerated, with vaginitis being the most common treatment-related adverse event in each group.
Conclusions: This study shows that single-dose grepafloxacin is at least as effective as cefixime for treating women with uncomplicated cervical gonorrhea. Grepafloxacin also appears to be highly effective against extragenital infections.
Full Text
The Full Text of this article is available as a PDF (523.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cook P. J., Andrews J. M., Wise R., Honeybourne D., Moudgil H. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother. 1995 Feb;35(2):317–326. doi: 10.1093/jac/35.2.317. [DOI] [PubMed] [Google Scholar]
- Kimura M., Kishimoto T., Niki Y., Soejima R. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. Antimicrob Agents Chemother. 1993 Apr;37(4):801–803. doi: 10.1128/aac.37.4.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Matsuda S. Clinical experience with OPC-17116 in the treatment of gynaecological infections and its penetration into gynaecological tissues. Japanese Collaborative Study Group of OPC-17116 in Gynaecology. Drugs. 1995;49 (Suppl 2):395–398. doi: 10.2165/00003495-199500492-00111. [DOI] [PubMed] [Google Scholar]
- Muytjens H. L., Heessen F. W. In vitro activities of thirteen beta-lactam antibiotics against Chlamydia trachomatis. Antimicrob Agents Chemother. 1982 Sep;22(3):520–521. doi: 10.1128/aac.22.3.520. [DOI] [PMC free article] [PubMed] [Google Scholar]
- O'Callaghan C. H., Morris A., Kirby S. M., Shingler A. H. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972 Apr;1(4):283–288. doi: 10.1128/aac.1.4.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schwarcz S. K., Zenilman J. M., Schnell D., Knapp J. S., Hook E. W., 3rd, Thompson S., Judson F. N., Holmes K. K. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project. JAMA. 1990 Sep 19;264(11):1413–1417. [PubMed] [Google Scholar]
- Sewell D. L., Barry A. L., Allen S. D., Fuchs P. C., Murray P. R., Tenover F. C. Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)). J Antimicrob Chemother. 1996 Jan;37(1):139–143. doi: 10.1093/jac/37.1.139. [DOI] [PubMed] [Google Scholar]
- Sivayathorn A. The use of fluoroquinolones in sexually transmitted diseases in Southeast Asia. Drugs. 1995;49 (Suppl 2):123–127. doi: 10.2165/00003495-199500492-00019. [DOI] [PubMed] [Google Scholar]
- Thomas J. C., Schoenbach V. J., Weiner D. H., Parker E. A., Earp J. A. Rural gonorrhea in the southeastern United States: a neglected epidemic? Am J Epidemiol. 1996 Feb 1;143(3):269–277. doi: 10.1093/oxfordjournals.aje.a008738. [DOI] [PubMed] [Google Scholar]
- Wise R., Andrews J. M., Brenwald N. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother. 1993 Apr;31(4):497–504. doi: 10.1093/jac/31.4.497. [DOI] [PubMed] [Google Scholar]
- Zenilman J. M., Neumann T., Patton M., Reichart C. Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1993 Oct;37(10):2244–2246. doi: 10.1128/aac.37.10.2244. [DOI] [PMC free article] [PubMed] [Google Scholar]